×
About 2,470 results

ALLMedicine™ Acute Promyelocytic Leukemia Center

Research & Reviews  923 results

Successful treatment and integrated genomic analysis of an infant with FIP1L1-RARA fusi...
https://doi.org/10.1182/bloodadvances.2021004966
Blood Advances; Miltiadous O, Petrova-Drus K et. al.

Sep 23rd, 2021 - FIP1L1-RARA associated neoplasm is a very rare and aggressive disease, with only 3 previously reported cases in the literature. Herein we describe a 9-month-old boy who presented with a FIP1L1-RARA fusion associated myelodysplastic/myeloproliferat...

Interdisciplinary Quality Improvement Led by the Molecular Pathology Laboratory Expedit...
https://doi.org/10.1093/ajcp/aqab137
American Journal of Clinical Pathology; Asadbeigi S, Zhou Y

Sep 22nd, 2021 - Acute promyelocytic leukemia (APL) requires emergent treatment while definitive laboratory results are pending. Following the death of a patient whose diagnosis was delayed, we sought to improve our institution's workflow by using the EPIDEM (Expl...

Long-Term Quality of Life of Acute Promyelocytic Leukemia Patients Treated with Arsenic...
https://doi.org/10.1182/bloodadvances.2021004649
Blood Advances; Efficace F, Platzbecker U et. al.

Sep 17th, 2021 - The main objective of this study was to compare the long-term health-related quality of life of patients with acute promyelocytic leukemia (APL) treated with all-trans retinoic acid (ATRA) plus arsenic trioxide (ATO) versus ATRA plus standard chem...

Impact of sociodemographic factors on early mortality in acute promyelocytic leukemia i...
https://doi.org/10.1002/cncr.33914
Cancer Jamy OH, Dhir A et. al.

Sep 9th, 2021 - The survival of patients with acute promyelocytic leukemia (APL) has dramatically improved with the use of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). However, because of the complexity of the initial management, early mortality (EM...

see more →

Guidelines  1 results

Acute myeloid leukemia, version 2.2013.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161234
Journal of the National Comprehensive Cancer Network : JN... O'Donnell MR, Tallman MS et. al.

Sep 14th, 2013 - These NCCN Guidelines Insights summarize several key updates to the NCCN Guidelines for Acute Myeloid Leukemia and discuss the clinical evidence that support the recommendations. The updates described in this article focus on the acute promyelocyt...

see more →

Drugs  11 results see all →

News  53 results

How to Treat Differentiation Syndrome in APL and AML
https://decisionpoint.medscape.com/oncology/viewarticle/936167

Sep 18th, 2020 - This transcript has been edited for clarity. Differentiation syndrome is a frequent complication while patients have active acute promyelocytic leukemia (APL). First of all, we need to mention that the diagnosis of differentiation syndrome is base...

Don't Overlook Treating Older Patients With Acute Promyelocytic Leukemia, Expert Says
https://www.medscape.com/viewarticle/934124

Jul 17th, 2020 - The estimated one third of patients with acute promyelocytic leukemia (APL) who are older than 60 years of age now enjoy a notably better prognosis than in years past, thanks to the introduction of all-trans retinoic acid (ATRA) and arsenic trioxi...

How a 100-Year-Old Formula Could Stop Lifesaving Cancer Therapy
https://www.medscape.com/viewarticle/917519

Aug 30th, 2019 - While leading his team on a hospital round, Joshua F. Zeidner, MD, saw a note recommending that arsenic trioxide (Trisenox, Teva) should be temporarily discontinued in a 44-year-old woman with acute promyelocytic leukemia (APL). The recommendation...

How a 100-Year-Old Formula Could Stop Lifesaving Cancer Therapy
https://www.staging.medscape.com/viewarticle/917519

Aug 30th, 2019 - While leading his team on a hospital round, Joshua F. Zeidner, MD, saw a note recommending that arsenic trioxide (Trisenox, Teva) should be temporarily discontinued in a 44-year-old woman with acute promyelocytic leukemia (APL). The recommendation...

see more →